RecruitingPhase 1 / Phase 2NCT05849662
Rare condition
Neurofibroma
53
studies recruiting now
as of 7 Sept 2026
345
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
24 Jan 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT05245500
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingNCT06222203
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
RecruitingPhase 2NCT04374305
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
RecruitingNCT02544022
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 53 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Neurofibroma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Neurofibroma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Selumetinib Sulfate (Koselugo)
Phase 2Luvometinib
Phase 1Deoxycholic Acid (Kybella)
Phase 1Talaporfin Sodium
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).